ClinicalTrials.gg
Not yet recruitingNCT07788898AI-CAREUpdated Sep 2, 2026

AI-enabled Communication to Advance Research Engagement (AI-CARE)

An interventional study of Community co-created AI summaries and Experimental: Researcher prompt engineering in Health Literacy and Health Communication, sponsored by Albert Einstein College of Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Primary conditionLiteracyRegistry: CommunicationReclassifiedWhy we changed it
Registry
Communication — the first condition term the registry derived for this study.
ClinicalTrials.gg
Literacy
Why
  1. The study's listed conditions name Literacy, a narrower term within Communication.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Albert Einstein College of Medicine · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of AI-CARE is to train researchers and community members to use artificial intelligence (AI) to create plain-language summaries of research studies and to determine whether a co-creation process for developing these summaries improves understanding and relevance of the research, confidence in AI and in institutions, and AI literacy. The hypothesis is that AI-generated research summaries, co-developed with researchers and community partners, will significantly improve confidence in research and institutions, understanding and accessibility of the research, and appropriateness of the summary compared with standard researcher-generated materials, and that the educational and co-creation process will build community members' AI literacy and confidence in using AI, as well as researchers' readiness to use and comfort with using AI for communicating research.

Read the detailed description

This research project consists of four specific aims. Specific Aims 2 and 3 meet the NIH definition of a clinical trial. Accordingly, this ClinicalTrials.gov registration describes only the clinical trial conducted under Specifics Aims 2 and 3. The remaining aims involve non-interventional research activities and are not included in this registration. Aims 2 and 3 are an intentional sequential design.

02

Conditions studied

  • Health Literacy
  • Health Communication

Browse trials for

Keywords

  • AI literacy
  • AI communication
03

In context

Literacy Reclassified

201 studies on the registry are indexed under Literacy; 69 are open to participants now.

This study's planned enrollment of 250 is above the median of 124 across 170 interventional studies indexed under Literacy.

Browse Literacy studies →

Lead sponsor

Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.

Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.

Compared within Literacy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Communication. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-speaking individuals at least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Individuals unable to provide
  • Participants who have had formal training in AI prompt engineering

The eligibility criteria are common to both Aims 2 and 3.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Standard AI prompt - Aim 3

    Participants receive plain-language research summaries generated using a standardized AI prompt without researcher prompt engineering or community co-design.

    Behavioral: Experimental: Standard AI prompt

  • Experimental
    Researcher prompt engineering - Aim 3

    Participants receive summaries generated after researchers complete AI prompt-engineering training and develop optimized prompts.

    Behavioral: Experimental: Researcher prompt engineering

  • Experimental
    Community co-created AI summaries - Aim 3

    Participants receive summaries developed through an iterative community-researcher co-creation process following AI training and structured co-design sessions.

    Behavioral: Community co-created AI summaries

  • Experimental
    Co-creation cohort - Aim 2

    Participants will be divided into three groups, each assigned 1-2 research summaries, and will engage in structured co-creation sessions. The goals of will be to: 1) define readability and appropriateness, 2) review AI-generated drafts produced by the summary engine, and 3) provide feedback to refine prompts and outputs. Several iteration cycles will be conducted as needed, with documentation of any changes and the rationale for making decisions. In this way the team will develop a modular AI "summary engine" that transforms research products (e.g., manuscripts) into draft community-facing materials using co-created prompts and templates. Co-creation will be conducted during one or two facilitated sessions. Each session will include structured review of drafts, guided discussion, and documented decisions regarding readability, transparency, visuals or graphics, etc. Iteration cycles will continue until pre-specified stopping criteria are met.

    Behavioral: AI literacy training and co-design

Interventions

  • BehavioralCommunity co-created AI summaries

    Participants review AI-generated summaries refined through iterative collaboration between researchers and community members using community-engaged co-design principles.

  • BehavioralExperimental: Researcher prompt engineering

    Participants review AI-generated summaries generated after researchers complete AI prompt-engineering training and develop optimized prompts.

  • BehavioralExperimental: Standard AI prompt

    Participants review plain-language research summaries generated using a standardized AI prompt without researcher prompt engineering or community co-design.

  • BehavioralAI literacy training and co-design

    The co-designed summaries which result from this process will become one of the three intervention conditions evaluated in Aim 3.

06

What researchers measure

Primary outcomes

  1. Confidence in medical research and researchers - Aim 3

    This is the primary outcome measure for both Aim 2 and Aim 3. This outcome measure will be assessed using subscale 1 of the PoRT scale. PoRT is a validated, self-report measure that assesses confidence in medical research and researchers. Subscale 1 contains 9 items, with response options for each item ranging from 1 (strongly disagree) to 5 (strongly agree); thus the subscale ranges from 9 to 45. Higher scores indicate higher confidence.

    Time frame: Immediately following review of research summary, up to 1 hour

  2. Confidence in medical research and researchers - Aim 2

    This is the primary outcome measure for both Aim 2 and Aim 3. This outcome measure will be assessed using subscale 1 of the PoRT scale. PoRT is a validated, self-report measure that assesses confidence in medical research and researchers. Subscale 1 contains 9 items, with response options for each item ranging from 1 (strongly disagree) to 5 (strongly agree); thus the subscale ranges from 9 to 45. Higher scores indicate higher confidence.

    Time frame: Immediately before the co-creation process and immediately following the co-creation process, up to 1 hour

Secondary outcomes

  1. Perceived appropriateness of research summary - Aim 2

    Perceived appropriateness of research summary will be assessed using an 8-item scale adapted from the literature which measures community and personal relevance, fit and respect, language and representation, and confidence and resonance (each of the four constructs is measured using two items). Responses for the eight items range from 1=strongly disagree to 5=strongly agree; possible scale score thus ranges from 8 to 40. Higher scores indicate higher perceived appropriateness.

    Time frame: Immediately before the co-creation process and immediately following the co-creation process, up to 1 hour

  2. Institutional confidence - Aim 2

    This is a validated measure of confidence in health care institutions, assessed using the MMI scale which contains 7 items. Responses range from 1 (strongly disagree) to 5 (strongly agree); thus, the range of scale scores is 7 to 35. Lower scores indicate higher confidence.

    Time frame: Immediately before the co-creation process and immediately following the co-creation process, up to 1 hour

  3. Research comprehension - Aim 2

    Research study specific comprehension which will consist of 25 true-false statements (5 items for each of the 5 research studies chosen by researchers and community participants that will be used for creation of plain-language summaries). Correct answers = 1, and incorrect answers = 0. The range will be 0 to 25, with higher scores indicating better comprehension.

    Time frame: Immediately before the co-creation process and immediately following the co-creation process, up to 1 hour

  4. Perceived appropriateness of research summary - Aim 3

    Perceived appropriateness of research summary will be assessed using an 8-item scale adapted from the literature which measures community and personal relevance, fit and respect, language and representation, and confidence and resonance (each of the four constructs is measured using two items). Responses for the eight items range from 1=strongly disagree to 5=strongly agree; possible scale score thus ranges from 8 to 40. Higher scores indicate higher perceived appropriateness.

    Time frame: Immediately following review of research summary, up to 1 hour

  5. Institutional confidence - Aim 3

    This is a validated measure of confidence in health care institutions, assessed using the MMI scale which contains 7 items. Responses range from 1 (strongly disagree) to 5 (strongly agree); thus, the range of scale scores is 7 to 35. Lower scores indicate higher confidence.

    Time frame: Aim 3: Immediately following review of research summary, up to 1 hour

  6. Research comprehension - Aim 3

    Research study specific comprehension which will consist of 25 true-false statements (5 items for each of the 5 research studies chosen by researchers and community participants that will be used for creation of plain-language summaries). Correct answers = 1, and incorrect answers = 0. The range will be 0 to 25, with higher scores indicating better comprehension.

    Time frame: Immediately following review of research summary, up to 1 hour

07

Study locations

1 site
08

References and documents

Publications

  • Shoemaker SJ, Wolf MS, Brach C. Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information. Patient Educ Couns. 2014 Sep;96(3):395-403. doi: 10.1016/j.pec.2014.05.027. Epub 2014 Jun 12. PubMed 24973195 ↗
  • Snyder HR, Miyake A, Hankin BL. Advancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approaches. Front Psychol. 2015 Mar 26;6:328. doi: 10.3389/fpsyg.2015.00328. eCollection 2015. PubMed 25859234 ↗
  • Marafino BJ, Dudley RA, Shah NH, Chen JH. Accurate and interpretable intensive care risk adjustment for fused clinical data with generalized additive models. AMIA Jt Summits Transl Sci Proc. 2018 May 18;2017:166-175. eCollection 2018. PubMed 29888065 ↗
  • O'Connor MA, Erasmus JH, Randall S, Archer J, Lewis TB, Brown B, Fredericks M, Groenier S, Iwayama N, Ahrens C, Garrison W, Wangari S, Guerriero KA, Fuller DH. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques. Front Immunol. 2021 Dec 21;12:800723. doi: 10.3389/fimmu.2021.800723. eCollection 2021. PubMed 34992610 ↗
  • Kreuter MW, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav. 2003 Nov-Dec;27 Suppl 3:S227-32. doi: 10.5993/ajhb.27.1.s3.6. PubMed 14672383 ↗
  • Holzer JK, Ellis L, Merritt MW. Why we need community engagement in medical research. J Investig Med. 2014 Aug;62(6):851-5. doi: 10.1097/JIM.0000000000000097. PubMed 24979468 ↗

Individual participant data

Plan to share: No — A data management and sharing plan was not created for this grant.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07788898
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Jessica Kahn, MD, MPH
Contact
jessica.kahn@einsteinmd.edu
718-430-4317
Jessica Kahn, MD, MPH
principal investigator · Albert Einstein College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion